Biotech

Breaking news and analysis on the biotech industry — covering drug development, clinical trials, IPOs, M&A, and the companies pushing biopharma forward.

Biotech

Exelixis’ Cabometyx successor misses primary endpoint in CRC trial

While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.

Angus Liu Jun 22, 2026 3:40pm

HHS unveils plan to speed up ph. 1 trials by 6 to 12 months

Jun 22, 2026 12:10pm

For biopharma manufacturing at speed and scale, the future is flexible

Brought to you by Resilience

Fierce Biotech Fundraising Tracker '26: Triveni Bio & more

Jun 22, 2026 11:00am

Redefining PSC success through endpoint research.

Brought to you by Ipsen

In another reversal, FDA to reconsider Regenxbio gene therapy

Jun 22, 2026 10:26am